YB-1: oncoprotein, prognostic marker and therapeutic target?

Biochem J. 2013 Jan 1;449(1):11-23. doi: 10.1042/BJ20121323.

Abstract

Hanahan and Weinberg have proposed the 'hallmarks of cancer' to cover the biological changes required for the development and persistence of tumours [Hanahan and Weinberg (2011) Cell 144, 646-674]. We have noted that many of these cancer hallmarks are facilitated by the multifunctional protein YB-1 (Y-box-binding protein 1). In the present review we evaluate the literature and show how YB-1 modulates/regulates cellular signalling pathways within each of these hallmarks. For example, we describe how YB-1 regulates multiple proliferation pathways, overrides cell-cycle check points, promotes replicative immortality and genomic instability, may regulate angiogenesis, has a role in invasion and metastasis, and promotes inflammation. We also argue that there is strong and sufficient evidence to suggest that YB-1 is an excellent molecular marker of cancer progression that could be used in the clinic, and that YB-1 could be a useful target for cancer therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Biomarkers, Tumor / physiology
  • Cell Proliferation / drug effects
  • Disease Progression
  • Drug Delivery Systems / methods*
  • Humans
  • Neoplasms / diagnosis*
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / metabolism
  • Oncogene Proteins / physiology
  • Prognosis
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Y-Box-Binding Protein 1 / physiology*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Oncogene Proteins
  • Y-Box-Binding Protein 1
  • YBX1 protein, human